[Untitled]

Remifentanil is a short-acting μ-opioid with a half-life of less than 9–10 min, metabolized by plasmatic esterasis. In this retrospective study, we evaluated the safety of remifentanil sedation (RS) versus midazolam–morphine sedation (MM) in 80 patients undergoing abdominal surgery. Our target was to assess whether RS is able to reduce times of weaning from mechanical ventilation with respect to MM sedation.